Standard Life Aberdeen plc increased its stake in shares of Core Laboratories (NYSE:CLB) by 27.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,500 shares of the oil and gas company’s stock after purchasing an additional 2,025 shares during the period. Standard Life Aberdeen plc’s holdings in Core Laboratories were worth $1,100,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CLB. Royal London Asset Management Ltd. raised its holdings in shares of Core Laboratories by 8,754.1% during the third quarter. Royal London Asset Management Ltd. now owns 1,520,160 shares of the oil and gas company’s stock valued at $171,578,000 after purchasing an additional 1,502,991 shares during the last quarter. Epoch Investment Partners Inc. raised its holdings in shares of Core Laboratories by 24.0% during the third quarter. Epoch Investment Partners Inc. now owns 1,419,317 shares of the oil and gas company’s stock valued at $164,399,000 after purchasing an additional 274,712 shares during the last quarter. Fisher Asset Management LLC raised its holdings in shares of Core Laboratories by 60.1% during the third quarter. Fisher Asset Management LLC now owns 721,408 shares of the oil and gas company’s stock valued at $83,561,000 after purchasing an additional 270,723 shares during the last quarter. WCM Investment Management CA raised its holdings in shares of Core Laboratories by 5.0% during the second quarter. WCM Investment Management CA now owns 5,285,156 shares of the oil and gas company’s stock valued at $667,040,000 after purchasing an additional 249,329 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Core Laboratories by 9,329.6% during the second quarter. Millennium Management LLC now owns 226,594 shares of the oil and gas company’s stock valued at $28,598,000 after purchasing an additional 224,191 shares during the last quarter.

Several research firms have recently weighed in on CLB. JPMorgan Chase & Co. cut shares of Core Laboratories from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $111.00 to $79.00 in a report on Tuesday, December 11th. Stifel Nicolaus upgraded shares of Core Laboratories from a “hold” rating to a “buy” rating and cut their target price for the company from $117.00 to $110.00 in a research report on Monday, October 29th. Zacks Investment Research restated a “sell” rating on shares of Core Laboratories in a research report on Monday, November 12th. Piper Jaffray Companies set a $70.00 target price on shares of Core Laboratories and gave the company a “hold” rating in a research report on Wednesday, December 26th. Finally, Morgan Stanley began coverage on shares of Core Laboratories in a research report on Tuesday, September 18th. They set an “equal weight” rating and a $125.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. Core Laboratories presently has a consensus rating of “Hold” and an average price target of $97.40.

CLB opened at $68.43 on Wednesday. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of 28.79, a PEG ratio of 3.33 and a beta of 1.83. Core Laboratories has a 1-year low of $56.72 and a 1-year high of $130.34. The company has a debt-to-equity ratio of 1.83, a current ratio of 2.31 and a quick ratio of 1.85.

Core Laboratories (NYSE:CLB) last posted its quarterly earnings results on Wednesday, October 24th. The oil and gas company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.01. The business had revenue of $182.15 million during the quarter, compared to analyst estimates of $178.11 million. Core Laboratories had a net margin of 13.21% and a return on equity of 68.00%. The company’s revenue was up 11.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.46 earnings per share. Equities research analysts anticipate that Core Laboratories will post 2.28 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/standard-life-aberdeen-plc-grows-stake-in-core-laboratories-clb/2749452.html.

About Core Laboratories

Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

Featured Story: Trading Ex-Dividend

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.